Multiple Sclerosis Relapsing Remitting Progressive Type

Authors

  • Nora Fitri Andalas University
  • Basjiruddin Ahmad Staff of Neurology Departement of Medical Facuilty of Andalas University / Dr. M. Djamil General Public Hospital, Padang
  • Yuliarni Syafrita Staff of Neurology Departement of Medical Facuilty of Andalas University / Dr. M. Djamil General Public Hospital, Padang

DOI:

https://doi.org/10.33533/jpm.v14i2.2208

Keywords:

auto imun, demyelination, lhermitte sign, multiple sclerosis

Abstract

Multiple sclerosis (MS) is the most common neurologic demyelinating disease in high-income countries. The causes of MS is multifactorial involve genetics and the environment in which immune cell infiltration occurs across the blood-brain barrier, causing inflammation, demyelination, gliosis, and neuroaxonal degeneration in the substantia grisea in the central nervous system. A 23-year-old female patient was treated with four limbs weakened since 2 weeks ago accompanied by blurred vision, pain, cramps and stiffness in the back muscles and legs. The patient has experienced the same complaint before. Clinical findings reveal lhermitte sign, atrophy papillae, and tetraparese. On thoracic vertebral MRI examination without contrast and brain MRI with contrast obtained multiple sclerosis lesions. Patients receive steroid and antidepressant therapy. MS needs to be studied further because this number of cases began to emerge.

 

Author Biography

Nora Fitri, Andalas University

Neurology

References

[1] Bellou V, Belbasis L, Tzoulaki I, Evangelou E, Ioannidis J. Environmental risk factors and Parkinson's disease: An umbrella review of meta-analyses. Parkinsonism & Related Disorders. 2016;23:1-9.

[2] Jácome Sánchez E, García Castillo M, González V, Guillén López F, Correa Díaz E. Coexistence of systemic lupus erythematosus and multiple sclerosis. A case report and literature review. Multiple Sclerosis Journal - Experimental, Translational and Clinical. 2018;4(2):1-9

[3] Dobson R, Giovannoni G. Autoimmune disease in people with multiple sclerosis and their relatives: a systematic review and meta-analysis. Journal of Neurology. 2013; 260(5): 1272-1285.

[4] Moutsianas L, Jostins L, Beecham A, Dilthey A, Xifara D, Ban M, et al. Class II HLA interactions modulate genetic risk for multiple sclerosis. Nature Genetics. 2015; 47(10): 1107-1113.

[5] Patsopoulos N. Genetics of Multiple Sclerosis: An Overview and New Directions. Cold Spring Harb Perspect Med. 2018; 5-12

[6] Hayes C, Nashold. FE. Vitamin D and multiple sclerosis. Vitamin D, Volume 2 : Health, disease, and therapeutics. Elsevier. 2018; 989-1023

[7] Bhigjee A, Bill P. Case report: multiple sclerosis and sle revisited. Medical Journal of Islamic Academy of Sciences. 1999; 12(3): 79-84

[8] Kaplin, A. Depression in multiple sclerosis. In Multiple Sclerosis Therapeutics. Ed.3. Ed. Cohen JA, Rudick RA. London: Informa Healthcare. 2007; 823-841

[9] Filippi M, Bar-or A, Piehl F, Preziosa P, Solari A, Vukusic S, Rocca MA. Multiple Sclerosis. Disease primer. 2018; 43(4): 1-27

[10] McDonnell GV. Clinical features of multiple sclerosis. In Multiple Sclerosis for the Practicing Neurologist. Volume 5. New York : Demos Medical Publishing. 2007; 7-18

[11] Bethoux F. Management of spasticity in multiple sclerosis. In Multiple Sclerosis Therapeutics. Ed.3. Ed. Cohen JA, Rudick RA. London: Informa Healthcare. 2007; 785-797

[12] Perdossi. Pedoman Diagnosis dan Tatalaksana Multipel Sklerosis di Indonesia. Badan Penerbit FKUI. 2015; 23-29

[13] Samkoff LM, Cohen JA, Goodman AD. Disease-modifying therapy for multiple sclerosis in clinical practise. In Multiple Sclerosis Therapeutics. Ed.3. Ed. Cohen JA, Rudick RA. London: Informa Healthcare. 2007; 721-744

[14] Kes VB, Zavoreo I, Seric V, Solter VV, Cesarik M, Hajnsek S, et al. Recommendations for diagnosis and management of multiple sclerosis. Acta Clin Crost. 2012; 51: 117-135

[15] Garg N, Weinstock-Guttman B. Treatment of pain, paresthesias and paroxysmal disorders in multiple sclerosis. In Multiple Sclerosis Therapeutics. Ed.3. Ed. Cohen JA, Rudick RA. London: Informa Healthcare. 2007; 845-862

[16] Krupp LB, McLinskey N, MacAllister WS. Fatique in multiple sclerosis. In Multiple Sclerosis Therapeutics. Ed.3. Ed. Cohen JA, Rudick RA. London: Informa Healthcare. 2007; 771-783

Downloads

Published

2020-12-10

How to Cite

Fitri, N., Ahmad, B., & Syafrita, Y. (2020). Multiple Sclerosis Relapsing Remitting Progressive Type. Jurnal Profesi Medika : Jurnal Kedokteran Dan Kesehatan, 14(2). https://doi.org/10.33533/jpm.v14i2.2208